Browse the evidence

The prevalence of obesity among youth with type 1 diabetes increased from 18.1% to 26.0% from 2008-2011 to 2020-2023.

Healthcare providers should be aware of the rising obesity rates in youth with T1D for better management strategies.

The prevalence of obesity among adults with type 1 diabetes rose from 30.5% to 38.1% from 2008-2011 to 2020-2023.

Healthcare providers should recognize the increasing obesity rates in adults with T1D for effective treatment planning.

GLP-1RA prescriptions significantly increased across all BMI categories among youth and adults with type 1 diabetes over the last 15 years.

Clinicians should consider the increasing use of GLP-1RAs in managing obesity in T1D patients.

Advancements in laparoscopic surgical technique have improved the safety and efficacy of bariatric metabolic surgery.

Surgeons should adopt new laparoscopic techniques to enhance patient outcomes in bariatric surgery.

Patients who received the fluid-filled IGB were more likely to require urgent evaluation or treatment compared to those treated with the gas-filled IGB.

Clinicians should be aware of the higher likelihood of complications with the fluid-filled IGB.

Recent insights into pathophysiological mechanisms suggest that OSA may be divided into distinct subgroups.

Understanding the subgroups in OSA may lead to more targeted treatments.

Recent drug candidates show a convincing reduction of sleep disordered breathing in both short and intermediate term.

New drug candidates may offer effective treatment options for OSA patients.

GLP-1RAs may have little or no effect on breast cancer risk.

Practitioners should consider that GLP-1RAs may not significantly increase breast cancer risk based on current evidence.

GLP-1RAs and dual GLP-1/GIPRA are associated with notable reductions in fat-free mass (FFM).

Practitioners should monitor FFM loss in patients undergoing GLP-1RA and GLP-1/GIPRA therapies.

The time of day does not significantly moderate the association between MVPA and all-cause mortality.

Patients can perform MVPA at any time of day without concern for timing affecting mortality.

Substituting evening MVPA with morning MVPA does not lead to appreciable changes in all-cause mortality.

The timing of MVPA (morning vs evening) is not critical for mortality outcomes.

A new sub-specialty, Cardiovascular-Endocrine-Metabolic Medicine, is proposed to unify care across multiple specialties.

Healthcare systems should consider integrating this new sub-specialty for improved patient outcomes.

The limited efficacy and adverse effects of available oral pharmacotherapies pose a significant obstacle in the fight against obesity.

Practitioners should be aware of the limitations of current oral obesity treatments.

A dual/poly-GPCR agonism strategy has emerged as an alternative approach to the traditional mono-GPCR concept.

Practitioners may consider exploring dual/poly-GPCR strategies in obesity treatment.

The mechanism-based therapeutic potential and limitations of oral poly-GPCR agonism strategy to augment intestinal GLP-1 for weight loss are projected.

Practitioners should evaluate the potential of oral poly-GPCR agonism in enhancing GLP-1 for weight loss.

The plant-based, low-fat diet resulted in substantially greater glucose and insulin levels.

Practitioners should be aware that a plant-based, low-fat diet may increase glucose and insulin levels.

Low fat intake is associated with a higher risk of all-cause dementia (HR 1.42 (95%CI: 1.11-1.82)).

Practitioners should be cautious about recommending very low fat diets for older adults due to potential dementia risk.

No leucine metabolite attenuated inflammation during training.

Leucine metabolites should not be recommended for reducing inflammation in resistance training.

By the fifth month, nearly one-half (46%) of semaglutide users had discontinued the treatment.

Practitioners should be aware of the high discontinuation rates when prescribing semaglutide.

Higher discontinuation rates were associated with lower household income and education level.

Socioeconomic factors should be considered when evaluating patient adherence to semaglutide.

Chronic co-administration of OXT and GLP-1 decreases body weight without changing food intake.

Combining OXT with GLP-1 may be an effective strategy for reducing body weight in obese populations.

Single injection of OXT/GLP-1 additively decreases food intake.

Using OXT in conjunction with GLP-1 may enhance appetite suppression effects.

If clinicians elect to use compounded incretin‐based therapy, they must consider the potential harms and benefits for each patient.

Clinicians should evaluate individual patient needs and educate them on therapy administration.

Obesity is associated with comorbidities such as metabolic and cardiovascular diseases, orthopaedic and psychiatric conditions, and cancer.

Healthcare providers should be aware of the serious health risks associated with obesity.